Structure-based drug design and the discovery of Aliskiren (Tekturna®): Perseverance and creativity to overcome a R&D pipeline challenge

Chemical Biology and Drug Design

Volumn 70, Issue 6, 2007, Pages 557-565

  Claude Cohen, Nissim ^a  

^a Synergix Ltd   (Israel)

Author keywords

Aliskirin; Drug Design; Drug Discovery; Nonpeptide; Structure Based Drug Design; Tekturna

Indexed keywords

5 CYCLOHEXYL 4 [N [3 ETHYLSULFONYL 2 (1 NAPHTHYLMETHYL)PROPIONYL]NORLEUCINAMIDO] 1 MORPHOLINO 2,3 PENTANEDIOL; ALISKIREN; CGP 38560; N BENZYLOXYCARBONYLARGINYLARGINYLPROLYLPHENYLALANYLHISTIDYLSTATINYLISOLEUCYL HISTIDYL (NEPSILON BUTYLOXYCARBONYLLYSINE) METHYL ESTER; N BENZYLOXYCARBONYLARGINYLARGINYLPROLYLPHENYLALANYLHISTIDYLSTATINYLISOLEUCYLHISTIDYL (NEPSILON BUTYLOXYCARBONYLLYSINE) METHYL ESTER; NALPHA [3 MORPHOLINOCARBONYL 2 (1 NAPHTHYLMETHYL)PROPIONYL]HISTIDINE N [1 CYCLOHEXYLMETHYL 2 HYDROXY 3 (1 METHYL 5 TETRAZOLYLTHIO)PROPYL]AMIDE; REMIKIREN; RENIN INHIBITOR; TEKTURNA; UNCLASSIFIED DRUG; ZANKIREN;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG MANUFACTURE; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; HYPERTENSION; LABORATORY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; UNITED STATES;

AMIDES; ANIMALS; BIOMIMETIC MATERIALS; DRUG APPROVAL; DRUG DESIGN; ENZYME INHIBITORS; FUMARATES; HUMANS; HYPERTENSION; MODELS, MOLECULAR; RENIN; STRUCTURE-ACTIVITY RELATIONSHIP; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 36348964763     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00599.x     Document Type: Article

References (9)

1. Wolfenden R (1972) Analog approaches to the structure of the transition state in enzyme reactions. Acc Chem Res 5 : 10 18.
2. Maibaum J, Rasetti V, Rüeger H, Cohen NC, Göschke R, Mah R, Rahuel J, Grütter M, Cumin F Wood JM. (1997) Design and Synthesis of Novel Potent, Non-Peptide and Orally Active Renin Inhibitors. In : Yamazaki, M., editor. Medicinal Chemistry Today and Tomorrow. Oxford, UK : Blackwell Science p. 155 162.
3. Rasetti V, Cohen NC, Rüeger H, Göschke R, Maibaum J, Cumin F, Fuhrer W, Wood JM. (1996) Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties, a novel strategy towards small non-peptide renin inhibitors. Bioorganic & Med. Chem Lett 6 : 1589 1594.
4. Göschke R, Cohen NC, Wood JM, Maibaum J. (1997) Design and syntheses of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl- octanecarboxamides-as in vitro potent peptidomimetic inhibitors of human renin. Bioorg Med Chem Lett 7 : 2735 2740.
5. Göschke R, Rasetti V, Cohen NC, Rahuel J, Baum HP, Forgiarini P, Schnell CR, Grütter MG, Stutz S, Rihs G, Wagner T, Fuhrer W, Cumin F, Wood JM, Maibaum J. (2007) Novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8- phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin. J Med Chem 50 : 4818 4831.
6. Maibaum J, Stutz S, Göschke R, Rigollier P, Yamaguchi Y, Cumin F, Rahuel J, Baum HP, Cohen NC, Schnell CR, Fuhrer W, Grütter MG, Schilling W, Wood JM. (2007) Structural modification of the P2' position of 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of Aliskiren, a potent non-peptide human renin inhibitor active after once daily dosing in marmosets. J Med Chem 50 : 4832 4844.
7. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüeger H et al. (2003) Structure-based design of Aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308 : 698 705.
8. Rahuel J, Rasetti V, Maibaum J, Rüeger H, Göschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM Grütter M. (2000). Structure based drug design: the discovery of novel non-peptide orally active inhibitors of human renin. Chem Biol 7 : 493 504.
9. Cohen NC. (1989) Molecular Mimics and Drug Design. In : der Goot H., Domany G., Pallos L., Timmerman H. editors. Trends in Medicinal Chemistry. Amsterdam, the Netherlands : Elsevier Science Publisher p. 13 28.